Cannabis Edibles: Blood and Oral Fluid Cannabinoid Pharmacokinetics and Evaluation of Oral Fluid Screening Devices for Predicting Δ9-Tetrahydrocannabinol in Blood and Oral Fluid following Cannabis Brownie Administration.

摘要: BACKGROUND: Roadside oral fluid (OF) Δ 9 -tetrahydrocannabinol (THC) detection indicates recent cannabis intake. OF and blood THC pharmacokinetic data are limited there no on-site screening performance evaluations after controlled edible cannabis. CONTENT: We reviewed cannabinoid pharmacokinetics of the Draeger DrugTest ® 5000 (DT5000) Alere™ DDS 2 (DDS2) devices. also present from a administration session. SUMMARY: maximum concentrations (C max ) were similar in frequent as compared to occasional smokers, while C higher [mean (range) 17.7 (8.0–36.1) μg/L] smokers [8.2 (3.2–14.3) smokers. Minor cannabinoids -tetrahydrocannabivarin cannabigerol never detected blood, not by 5 or 8 h, respectively, with 0.3 μg/L cutoffs. Recommended (analytical sensitivity, specificity, efficiency) criteria for devices ≥80% difficult meet when maximizing true positive (TP) results confirmation cutoffs below cutoff. TPs greatest ≥1 ≥2 μg/L, but analytical sensitivities 80% an ≥5 Performance >80% cutoff; however, might confirm due time required collect crash police stop. is recommended roadside screening. ClinicalTrials.gov identification number: NCT02177513